Research Topics

Genomes and Genes


Scott M Dehm


Affiliation: University of Minnesota
Country: USA


  1. Kohli M, Ho Y, Hillman D, Van Etten J, Henzler C, Yang R, et al. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance. Clin Cancer Res. 2017;23:4704-4715 pubmed publisher
    ..0; 95% confidence interval, 1.31-12.2; P = 0.02).Conclusions: AR-V9 may be an important component of therapeutic resistance in CRPC. Clin Cancer Res; 23(16); 4704-15. ©2017 AACR. ..
  2. Dehm S, Schmidt L, Heemers H, Vessella R, Tindall D. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469-77 pubmed publisher
    ..Together, our data describe a simple and effective mechanism by which PCa cells can synthesize a constitutively active AR and thus circumvent androgen ablation. ..
  3. Chan S, Selth L, Li Y, Nyquist M, Miao L, Bradner J, et al. Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. Nucleic Acids Res. 2015;43:5880-97 pubmed publisher
  4. Dehm S. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res. 2013;73:5309-14 pubmed publisher
    ..In this review, the role of splice variants in cancer therapy resistance will be discussed, with examples of how mechanistic understanding of these processes has led to the development of novel strategies for therapy resensitization. ..
  5. Van Etten J, Dehm S. Clonal origin and spread of metastatic prostate cancer. Endocr Relat Cancer. 2016;23:R207-17 pubmed publisher
    ..In this review, we highlight these recent insights into the spatiotemporal landscape of genetic evolution of prostate cancer. ..
  6. Li Y, Dehm S. Methods for Identifying and Quantifying mRNA Expression of Androgen Receptor Splicing Variants in Prostate Cancer. Methods Mol Biol. 2016;1443:165-77 pubmed publisher
  7. Luo J, Attard G, Balk S, Bevan C, Burnstein K, Cato L, et al. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018;73:715-723 pubmed publisher
    ..Detection of AR variants (eg, AR-V7) identified a patient population with poor outcomes to existing AR-targeting therapies, highlighting the need for novel therapeutic agents currently under development. ..
  8. Yang R, Van Etten J, Dehm S. Indel detection from DNA and RNA sequencing data with transIndel. BMC Genomics. 2018;19:270 pubmed publisher
  9. Daniel M, Dehm S. Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer. J Steroid Biochem Mol Biol. 2017;166:28-37 pubmed publisher
    ..Questions regarding the utility of AR-V measurements to provide prognostic information or predict patient responses to AR-targeted therapies will be addressed. ..

More Information


  1. Van Etten J, Nyquist M, Li Y, Yang R, Ho Y, Johnson R, et al. Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer. Cancer Res. 2017;77:5228-5235 pubmed publisher
    ..Our findings support the development of new therapies targeting the polyadenylation signal in AR intron 3 as a strategy to prevent expression of a broad array of AR variants in CRPC. Cancer Res; 77(19); 5228-35. ©2017 AACR. ..